Literature DB >> 27177628

An allograft mouse model for the study of hearing loss secondary to vestibular schwannoma growth.

Nicolas-Xavier Bonne1,2, Jérémie Vitte3,4, Fabrice Chareyre1, Gevorg Karapetyan5, Vazgen Khankaldyyan5, Karo Tanaka1, Rex A Moats5, Marco Giovannini6,7.   

Abstract

Vestibular schwannoma is a benign neoplasm arising from the Schwann cell sheath of the auditory-vestibular nerve. It most commonly affects both sides in the genetic condition Neurofibromatosis type 2, causing progressive high frequency sensorineural hearing loss. Here, we describe a microsurgical technique and stereotactic coordinates for schwannoma cell grafting in the vestibular nerve region that recapitulates local tumor growth in the cerebellopontine angle and inner auditory canal with resulting hearing loss. Tumor growth was monitored by bioluminescence and MRI in vivo imaging, and hearing assessed by auditory brainstem responses. These techniques, by potentially enabling orthotopic grafting of a variety of cell lines will allow studies on the pathogenesis of tumor-related hearing loss and preclinical drug evaluation, including hearing endpoints, for NF2-related and sporadic schwannomas.

Entities:  

Keywords:  Auditory brainstem response; Mouse model; Neurofibromatosis type 2; Vestibular schwannoma

Mesh:

Year:  2016        PMID: 27177628     DOI: 10.1007/s11060-016-2150-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  42 in total

1.  Low-frequency hearing loss after spinal anesthesia. Perilymphatic hypotonia?

Authors:  A Walsted; G Salomon; K S Olsen
Journal:  Scand Audiol       Date:  1991

2.  Incidence of vestibular schwannomas in the United States.

Authors:  Varun R Kshettry; Jason K Hsieh; Quinn T Ostrom; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  J Neurooncol       Date:  2015-05-30       Impact factor: 4.130

3.  Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2.

Authors:  M Giovannini; E Robanus-Maandag; M van der Valk; M Niwa-Kawakita; V Abramowski; L Goutebroze; J M Woodruff; A Berns; G Thomas
Journal:  Genes Dev       Date:  2000-07-01       Impact factor: 11.361

4.  [Hearing loss after spinal anesthesia. An audiological controlled trial].

Authors:  A Walsted; G Salomon; K S Olsen
Journal:  Ugeskr Laeger       Date:  1993-09-20

5.  Hearing loss after neurosurgery. The influence of low cerebrospinal fluid pressure.

Authors:  A Walsted; O A Nielsen; P Borum
Journal:  J Laryngol Otol       Date:  1994-08       Impact factor: 1.469

6.  Growth of human acoustic neuromas, neurofibromas and schwannomas in the subrenal capsule and sciatic nerve of the nude mouse.

Authors:  J K Lee; R A Sobel; E A Chiocca; T S Kim; R L Martuza
Journal:  J Neurooncol       Date:  1992-10       Impact factor: 4.130

7.  Bioluminescent imaging of intracranial vestibular schwannoma xenografts in NOD/SCID mice.

Authors:  Brian A Neff; Stephen G Voss; Cory Allen; Mark A Schroeder; Colin L W Driscoll; Michael J Link; Evanthia Galanis; Jann N Sarkaria
Journal:  Otol Neurotol       Date:  2009-01       Impact factor: 2.311

8.  Comparative pathology of nerve sheath tumors in mouse models and humans.

Authors:  Anat O Stemmer-Rachamimov; David N Louis; Gunnlaugur P Nielsen; Cristina R Antonescu; Alexander D Borowsky; Roderick T Bronson; Dennis K Burns; Pascale Cervera; Margaret E McLaughlin; Guido Reifenberger; Michael C Schmale; Mia MacCollin; Richard C Chao; Karen Cichowski; Michel Kalamarides; Shanta M Messerli; Andrea I McClatchey; Michiko Niwa-Kawakita; Nancy Ratner; Karlyne M Reilly; Yuan Zhu; Marco Giovannini
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

9.  Preoperative speech and pure-tone audiometry in four types of patients with acoustic neuroma.

Authors:  Thierry Morlet; Christian Dubreuil; Roland Duclaux; Chantal Ferber-Viart
Journal:  Am J Otolaryngol       Date:  2003 Sep-Oct       Impact factor: 1.808

10.  Analysis of mutations in the SCH gene in schwannomas.

Authors:  E K Bijlsma; P Merel; D A Bosch; A Westerveld; O Delattre; G Thomas; T J Hulsebos
Journal:  Genes Chromosomes Cancer       Date:  1994-09       Impact factor: 5.006

View more
  5 in total

1.  Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models.

Authors:  Yingchao Zhao; Pinan Liu; Na Zhang; Jie Chen; Lukas D Landegger; Limeng Wu; Fu Zhao; Yanxia Zhao; Yanling Zhang; Jing Zhang; Takeshi Fujita; Anat Stemmer-Rachamimov; Gino B Ferraro; Hao Liu; Alona Muzikansky; Scott R Plotkin; Konstantina M Stankovic; Rakesh K Jain; Lei Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-09       Impact factor: 11.205

2.  Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2.

Authors:  Shilpa Prabhakar; Roberta L Beauchamp; Pike See Cheah; Akiko Yoshinaga; Edwina Abou Haidar; Sevda Lule; Gayathri Mani; Katia Maalouf; Anat Stemmer-Rachamimov; David H Jung; D Bradley Welling; Marco Giovannini; Scott R Plotkin; Casey A Maguire; Vijaya Ramesh; Xandra O Breakefield
Journal:  Mol Ther Methods Clin Dev       Date:  2022-06-22       Impact factor: 5.849

3.  A Xenograft Model of Vestibular Schwannoma and Hearing Loss.

Authors:  Christine T Dinh; Olena Bracho; Christine Mei; Esperanza Bas; Cristina Fernandez-Valle; Fred Telischi; Xue-Zhong Liu
Journal:  Otol Neurotol       Date:  2018-06       Impact factor: 2.311

4.  Fluorescent Detection of Merlin-deficient Schwann Cells and Primary Human Vestibular Schwannoma Cells Using Sodium Fluorescein.

Authors:  Enrique R Perez; Olena Bracho; Liliana Ein; Mikhaylo Szczupak; Paula V Monje; Cristina Fernandez-Valle; Abdulaziz Alshaiji; Michael Ivan; Jacques Morcos; Xue-Zhong Liu; Michael Hoffer; Adrien Eshraghi; Simon Angeli; Fred Telischi; Christine T Dinh
Journal:  Otol Neurotol       Date:  2018-09       Impact factor: 2.311

5.  Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma.

Authors:  Jessica E Sagers; Roberta L Beauchamp; Yanling Zhang; Sasa Vasilijic; Limeng Wu; Patrick DeSouza; Richard Seist; Wenjianlong Zhou; Lei Xu; Vijaya Ramesh; Konstantina M Stankovic
Journal:  Sci Rep       Date:  2020-03-06       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.